{"id":540549,"date":"2025-01-14T10:01:39","date_gmt":"2025-01-14T13:01:39","guid":{"rendered":"https:\/\/revistapesquisa.fapesp.br\/?p=540549"},"modified":"2025-01-14T10:01:39","modified_gmt":"2025-01-14T13:01:39","slug":"anti-hiv-medication-still-poorly-distributed","status":"publish","type":"post","link":"https:\/\/revistapesquisa.fapesp.br\/en\/anti-hiv-medication-still-poorly-distributed\/","title":{"rendered":"Anti-HIV medication still poorly distributed"},"content":{"rendered":"<div id=\"attachment_540464\" style=\"max-width: 1150px\" class=\"wp-caption alignright vertical\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-540464 size-full\" src=\"https:\/\/revistapesquisa.fapesp.br\/wp-content\/uploads\/2025\/01\/RPF-notas-comprimido-aids-2024-07-1140.jpg\" alt=\"\" width=\"1140\" height=\"630\" srcset=\"https:\/\/revistapesquisa.fapesp.br\/wp-content\/uploads\/2025\/01\/RPF-notas-comprimido-aids-2024-07-1140.jpg 1140w, https:\/\/revistapesquisa.fapesp.br\/wp-content\/uploads\/2025\/01\/RPF-notas-comprimido-aids-2024-07-1140-250x138.jpg 250w, https:\/\/revistapesquisa.fapesp.br\/wp-content\/uploads\/2025\/01\/RPF-notas-comprimido-aids-2024-07-1140-700x387.jpg 700w, https:\/\/revistapesquisa.fapesp.br\/wp-content\/uploads\/2025\/01\/RPF-notas-comprimido-aids-2024-07-1140-120x66.jpg 120w\" sizes=\"auto, (max-width: 1140px) 100vw, 1140px\" \/><p class=\"wp-caption-text\"><span class=\"media-credits-inline\">Eduardo Cesar\u2009\/\u2009Revista Pesquisa FAPESP<\/span>PrEP pills, recommended for people without HIV who are at risk of being infected<span class=\"media-credits\">Eduardo Cesar\u2009\/\u2009Revista Pesquisa FAPESP<\/span><\/p><\/div>\n<p>Pre-exposure prophylaxis (PrEP) \u2014 a daily pill used to prevent the transmission of HIV, which causes AIDS \u2014 was made available through Brazil\u2019s public health system in 2018. Between that year and 2022, it was used by 124,796 people. There were, however, regional disparities influenced by socioeconomic factors, according to a study by a group from the Federal University of Sergipe (UFS). Based on data from Brazil\u2019s Ministry of Health, the Brazilian Institute of Geography and Statistics (IBGE), the Institute of Applied Economic Research (IPEA), and the Brazilian Medical Council (CFM), the group\u2019s analysis indicated that over the five years, PrEP was most used in cities with greater population densities and more doctors and health centers, especially in the states of Minas Gerais (112.8 users per 100,000 inhabitants), S\u00e3o Paulo (104.1 per 100,000), and Santa Catarina (87.7). The lowest proportions of users were recorded in the Federal District (4.1), Maranh\u00e3o (11.6), and Alagoas (12.9). The 667 health centers capable of providing the medication were located in just 414 municipalities (7.4% of the national total): 163 were in the state of S\u00e3o Paulo and 161 were in Rio de Janeiro; conversely, Alagoas and Tocantins had only two each, Acre and Amap\u00e1, four, and the Federal District and Para\u00edba, five. \u201cBrazil is in the top 10 countries worldwide in the number of PrEP users, but we face significant challenges related to misinformation and stigma, which limit access to this HIV prevention strategy,\u201d says Dr. Paulo Martins-Filho, head of the research group. \u201cIt is critical to address these challenges and expand access to PrEP to maximize its preventive potential,\u201d (<a href=\"https:\/\/revistapesquisa.fapesp.br\/en\/a-barrier-against-hiv\/\" target=\"_blank\" rel=\"noopener\"><em>Pesquisa FAPESP <\/em>issue n\u00ba 267<\/a>;<em> International Journal of STD &amp; AIDS<\/em>, May 8).<\/p>\n","protected":false},"excerpt":{"rendered":"Distribution of preventive HIV medicine concentrated in major cities","protected":false},"author":475,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[1651],"tags":[247,232,260,256],"coauthors":[785],"class_list":["post-540549","post","type-post","status-publish","format-standard","hentry","category-notes","tag-medicine","tag-pharmacology","tag-public-health","tag-public-policies"],"acf":[],"_links":{"self":[{"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/posts\/540549","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/users\/475"}],"replies":[{"embeddable":true,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/comments?post=540549"}],"version-history":[{"count":1,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/posts\/540549\/revisions"}],"predecessor-version":[{"id":540550,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/posts\/540549\/revisions\/540550"}],"wp:attachment":[{"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/media?parent=540549"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/categories?post=540549"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/tags?post=540549"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/coauthors?post=540549"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}